References
- Taïeb A, Picardo M. Clinical practice. Vitiligo. N Engl J Med 2009;360:160–169.
- Jin Y, Mailloux CM, Gowan K, Riccardi SL, LaBerge G, Bennett DC et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 2007;356:1216–1225.
- Yu HS, Chang KL, Yu CL, Li HF, Wu MT, Wu CS et al. Alterations in IL-6, IL-8, GM-CSF, TNF-alpha, and IFN-gamma release by peripheral mononuclear cells in patients with active vitiligo. J Invest Dermatol 1997;108:527–529.
- Moretti S, Spallanzani A, Amato L, Hautmann G, Gallerani I, Fabiani M et al. New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res 2002;15:87–92.
- Tu CX, Gu JS, Lin XR. Increased interleukin-6 and granulocyte-macrophage colony stimulating factor levels in the sera of patients with non-segmental vitiligo. J Dermatol Sci 2003;31:73–78.
- Swope VB, Abdel-Malek Z, Kassem LM, Nordlund JJ. Interleukins 1 alpha and 6 and tumor necrosis factor-alpha are paracrine inhibitors of human melanocyte proliferation and melanogenesis. J Invest Dermatol 1991;96:180–185.
- Kim NH, Jeon S, Lee HJ, Lee AY. Impaired PI3K/Akt activation-mediated NF-kappaB inactivation under elevated TNF-alpha is more vulnerable to apoptosis in vitiliginous keratinocytes. J Invest Dermatol 2007;127:2612–2617.
- Rigopoulos D, Gregoriou S, Larios G, Moustou E, Belayeva-Karatza E, Kalogeromitros D. Etanercept in the treatment of vitiligo. Dermatology (Basel) 2007;215:84–85.
- Simon JA, Burgos-Vargas R. Vitiligo improvement in a patient with ankyosing spondylitis treated with infliximab. Dermatology 2008;216:234–235.
- Campanati A, Giuliodori K, Ganzetti G, Liberati G, Offidani AM. A patient with psoriasis and vitiligo treated with etanercept. Am J Clin Dermatol 2010;11 Suppl 1:46–48.